Impact of radioiodine therapy on recurrence and survival outcomes in intermediate‐risk papillary thyroid carcinoma —A systematic review and meta‐analysis
Pooled result · Structural disease recurrenceResult — go to the resultPooled univariate OR 0.73 95% CI 0.29–1.87Authors' conclusion
This meta-analysis did not establish a conclusive benefit of RAI therapy in preventing structural disease recurrence or improving recurrence-free survival in intermediate-risk PTC. However, these results need to be interpreted with caution owing to significant heterogeneity in the existing literature. A prospective, randomised clinical trial is the need of the hour to better understand the effect of RAI therapy on long-term outcomes.
Study context
- Population
- Intermediate-risk papillary thyroid carcinoma (PTC) patients; articles January 2008 to March 2023 (PubMed, Scopus, EMBASE)11 articles
- Participants
- 56,266 patients
- Comparison
- Postoperative radioiodine (RAI) therapy vs no-RAI follow-up
- RAIn = 41,530
- NOIn = 14,736reference
- Outcome
- Structural disease recurrence
Pooled result
As reported in the abstract
Pooled univariate OR
0.73
95% CI 0.29–1.87
RAIvs NOI
pooled univariate OR 0.73 (95% CI 0.29–1.87)
Further pooled results
| Outcome | Pooled multivariate HR (95% CI) | |
|---|---|---|
| Recurrence-free survivalI2 = 94%; not significant | 0.21 (0.01–3.74) | |
| Overall survivalI2 = 79% | 0.63 (0.48–0.82) | |
| 0.050.21520Pooled multivariate HR (log scale) |
Original publication
Impact of radioiodine therapy on recurrence and survival outcomes in intermediate‐risk papillary thyroid carcinoma —A systematic review and meta‐analysis. Clin Endocrinol (Oxf). Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →